Compare Stocks → Biden replacement revealed? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ACUSOTCMKTS:ADDXFOTCMKTS:IMUCOTCMKTS:NEVPF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.05N/A-1.522 shsN/AADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AIMUCEOM Pharmaceuticals$0.20$0.21$0.11▼$0.40N/A0.373,695 shs392 shsNEVPFAbliva AB (publ)$0.01$0.01$0.01▼$0.02N/AN/AN/AN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%0.00%ADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%IMUCEOM Pharmaceuticals0.00%0.00%+30.20%-49.26%-5.81%NEVPFAbliva AB (publ)0.00%0.00%0.00%-50.00%0.00%Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourselfMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphereN/AN/AN/AN/AADDXFAddex TherapeuticsN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/A$0.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00N/AN/AN/AN/AN/AN/AADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ANEVPFAbliva AB (publ)-$8.45MN/A0.00∞N/AN/A-63.75%-57.93%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AADDXFAddex TherapeuticsN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AADDXFAddex TherapeuticsN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/ANEVPFAbliva AB (publ)N/A6.606.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AADDXFAddex TherapeuticsN/AIMUCEOM PharmaceuticalsN/ANEVPFAbliva AB (publ)N/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ADDXFAddex TherapeuticsN/AIMUCEOM Pharmaceuticals3.28%NEVPFAbliva AB (publ)N/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableADDXFAddex Therapeutics26N/AN/ANot OptionableIMUCEOM Pharmaceuticals3N/AN/ANot OptionableNEVPFAbliva AB (publ)8N/AN/ANot OptionableIMUC, NEVPF, ACUS, and ADDXF HeadlinesSourceHeadlineProbi ABbarrons.com - March 20 at 6:04 PMIVSXF Investor AB (publ)seekingalpha.com - January 10 at 12:59 AMInterfox Resources publ AB (IFOX)investing.com - October 3 at 12:53 AMOklahoma public higher ed leaders work to climb back from decade of cutstulsaworld.com - March 19 at 7:57 PMOrangeburg Department of Public Safety: Woman reports sexual assaultthetandd.com - March 18 at 5:23 PMResolutions at the Extraordinary General Meeting in Abliva AB (publ)privataaffarer.se - March 10 at 7:31 PMCell Impact publ AB (CELLI)investing.com - October 14 at 7:21 AMAbliva AB (publ) (NEVPF)nasdaq.com - January 20 at 8:12 PMCompany DescriptionsAcusphereOTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.Addex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.EOM PharmaceuticalsOTCMKTS:IMUCImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Abliva AB (publ)OTCMKTS:NEVPFAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.